There are two interesting points in this Nobel Prize in Chemistry.
The first point is that click chemistry and bioorthogonal chemistry are both proper terms that the public cannot intuitively understand. Based on simple popular science, players who have received 9-year compulsory education generally have a general understanding.
Click the word actually comes from click, which means it is like a seat belt, and it is buckled with a snap.
The so-called click chemistry is like Lego building blocks , connecting more macromolecular compounds together. It is to use a series of reliable and modular reactions to produce heteroatom-containing compounds. This technology is currently widely used in many research fields such as drug research and development and molecular biology .
orthogonality appears in junior high school physics, which is a kind of "vertical", such as "orthogonal decomposition of force" decomposes force into two vertical directions, which will not interfere with each other, which is convenient for research. Since higher animals do not contain alkyne bonds, they will not interfere with fluorescence signals, which is bioorthogonality.
The second point is that K. Barry Sharpless won the Nobel Prize in Chemistry as early as 2001. In the history of Nobel Prize , only a handful of people have won it twice. After all, even Einstein has won it only once.
Before him, only four master scientists won the Nobel Prize twice.
Madam Curie (Nobel Prize in Chemistry and Nobel Prize in Physics );
Bowling (Nobel Prize in Chemistry and Nobel Peace Prize , generally believed that the Peace Prize does not count very much);
Badin (two Nobel Prize in Physics);
Sanger (two Nobel Prize in Chemistry).
Chemistry awards in recent years have been awarded to technologies for researching new drugs.
Starry Sky Jun and his PhD junior in organic chemistry talked about this. Sure enough, the end of chemistry is medicine.
As a big shot, K. Barry Sharpless has in-depth exchanges with many Chinese institutions, schools and enterprises. He serves as honorary professors at many Chinese universities and cooperates with many Chinese colleagues.
For example, Barry Sharpless is also an honorary professor at Shanghai Institute of Organic Chemistry .
For example, Dr. Li Li studied and worked in Barry Sharples's laboratory and studied under Professor Wu Peng, the successful disciple of Barry Sharples.
Dr. Li Jie is now a professor of at Nanjing University. His research direction highlights the research characteristics of chemical tools + tumor immuno, explores the cutting-edge direction of chemistry and immunology, and gives full play to the advantages of chemical tools such as click chemistry, sugar chemistry and directional evolution in the research of basic immunology problems and the development of new immunotherapy.
In the field of bioorthogonality, , director of the Department of Chemical Biology, Peking University, , Professor Chen Peng, , is a top expert in the world. He was hired as the executive editor of the journal ACS ChemicalBiology in 2022.
The two have collaborated to win the second prize in the National Natural Science Prize: Development and Application of Live Cell Chemical Reaction Tools.
Coincidentally, Professor Chen Peng and Dr. Li Li are both working as scientific consultants for a startup.
This company is called Nanjing Keluosi Biotechnology Co., Ltd., and was established in March 2021.
company official website shows that this is a domestic biotechnology enterprise based in the interdisciplinary field of chemical biology, which was called by scientists from Peking University and Nanjing University and organized high-level overseas returnees.
Keluosibiology's previous-edge chemistry proteomics technology as the core, and its main business covers the research and development and production of protein chemical labeling technology services and related chemical probes. It strives to build a one-stop chemical multi-dimensional chemistry omics R&D and service platform to meet the needs of universities and corporate customers in drug target identification, protein target discovery and covalent drug pilot compound screening, and is committed to promoting precision medical research.
And the major shareholder of this company is Nanjing Yaoshi Technology .
Yaoshi Technology founder was once the deputy director of the R&D Center of Roche R&D (China) Co., Ltd., and attracted overseas returnee technology tycoons to join. Especially in the pharmaceutical industry, more and more technical tycoons have returned from studying abroad and started their own businesses. After the industrial upgrading of new energy vehicles, photovoltaic and other fields begins to show results, the pharmaceutical industry will soon become the next new track for industrial upgrading.
